Supplementary Materials
SAEs
Table S1: Treatment-emergent AEs and SAEs in patients with <1,500 neutrophils/Click here for additional data file.Distribution of baseline neutrophil counts in patients in the ITT population and in those with blood eosinophils ≥ 150 cells/Annualized severe exacerbation rates over the treatment period in patients with elevated type 2 biomarkers with or without elevated neutrophil counts at baseline. CI = confidence interval; FeNO = fractional exhaled nitric oxide; neutr = neutrophils; ppb = parts per billion; q2w = every 2 weeks.  Change from baseline in prebronchodilator FEV(a–d) Change in annualized severe exacerbation rates over the treatment period and change from baseline in prebronchodilator FEVBaseline characteristics for patients with elevated type 2 biomarkers with or without elevated neutrophil counts at baseline.
